Clopidogrel Tablet, Film Coated
Product Images NDC 13668-141

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 13668-141). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 01

Chemical structure diagram of Clopidogrel, showing molecular arrangement including a thiophene ring, ester group, and chlorophenyl moiety, along with associated H2SO4. The image depicts the chemical formula relevant to the active ingredient Clopidogrel.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 02

A forest plot chart showing the effect of co-administered proton pump inhibitors (PPIs) dexlanosoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg on active metabolite AUC of clopidogrel. The chart presents mean values with 90% confidence intervals and compares changes relative to clopidogrel tablets administered alone.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 03

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares placebo (+ aspirin) and Clopidogrel bisulfate (+ aspirin) treatments, with Clopidogrel showing a lower cumulative event rate throughout. The graph includes a statistical significance value (P=0.00009).*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 04

A forest plot showing hazard ratios with 95% confidence intervals for patient baseline characteristics and on-study concomitant medications/interventions in the CURE Study. The chart compares Clopidogrel versus placebo across subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke, concluding with overall hazard ratios.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 05

A hazard ratio forest plot from the CURE Study illustrating patient baseline characteristics and on-study concomitant medications for Clopidogrel versus placebo. Subgroups include Heparin/LMWH, Aspirin dosages, GPIIb/IIIa Antagonists, Beta-Blockers, and ACE Inhibitors, showing hazard ratios with confidence intervals favoring Clopidogrel or placebo, along with patient counts and event percentages for each group.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 06

A line graph titled 'Cumulative Event Rates for Death in the COMMIT Study' comparing death rates before first discharge over 28 days between placebo and Clopidogrel groups. The y-axis shows percentage dead before discharge, and the x-axis shows days since randomization. The graph notes 8.1% deaths for placebo and 7.5% for Clopidogrel, indicating a 7% proportional risk reduction (p=0.03). A footnote states all patients received aspirin.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 07

A line graph showing percentage incidence of death, re-infarction, or stroke before first discharge over days since randomization (up to 28 days) comparing placebo and Clopidogrel groups. The graph notes events in placebo (10.1%) and Clopidogrel (9.2%) groups and a 9% proportional risk reduction (p=0.002). All patients received aspirin.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 08

A forest plot figure showing the effects of adding Clopidogrel bisulfate to aspirin on combined primary endpoints across various baseline and concomitant medication subgroups in the COMMIT study, including gender, age, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent use, with odds ratios and confidence intervals comparing Clopidogrel to placebo.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 09

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over months of follow-up (0 to 36) comparing aspirin and clopidogrel bisulfate. Two lines plot event rates, with aspirin showing a higher rate than clopidogrel bisulfate. A p-value of 0.045 is indicated on the graph.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 10

A forest plot comparing Clopidogrel and Aspirin across qualifying conditions: Stroke, MI, PAD, and overall. It shows the number of cases and percentages for each drug group, with hazard ratio and 95% confidence intervals on the x-axis from 0.6 to 1.3. The plot visually indicates which treatment is favored for each condition using diamond markers.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 11

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 12

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 13

Clopidogrel Tablets, USP 75 mg film-coated oral tablets in a pack of 30, labeled for human prescription use. The label shows the NDC 13668-141-30 and indicates the product is manufactured by Torrent Pharmaceuticals Limited. It includes storage instructions and advises pharmacists to dispense the accompanying medication guide and directs Rx only use.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 14

Label for Clopidogrel Tablets, USP 75 mg film-coated tablets in a 30-tablet package. Manufactured by Torrent Pharmaceuticals Limited and labeled with NDC 13668-141-30. Label includes dosage strength, storage instructions, prescription status (Rx only), and pharmacist dispensing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.